LogoPressRelease.jpg
Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR  Assay for COVID-19
25 août 2020 23h00 HE | Fluidigm Corporation
Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment Extraction-Free, Real-Time PCR Workflow with Capacity of up to 6,000 Tests per Day per System  Demonstrated 100 Percent...
LogoPressRelease.jpg
Fluidigm Announces Conference Call and Webcast of First Quarter 2020 Financial Results
20 avr. 2020 16h06 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Fluidigm and SIgN Establish the First Center of Excellence in Singapore to Advance Imaging Mass Cytometry
11 mars 2020 08h30 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Fluidigm to Participate in Upcoming Investor Conferences
12 févr. 2020 16h05 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Fluidigm Announces Fourth Quarter and Full Year 2019 Financial Results
10 févr. 2020 16h05 HE | Fluidigm Corporation
Fourth quarter revenue of $32.4 million Full year 2019 revenue increased 4 percent to $117.2 million; full year mass cytometry revenue increased 23 percent Landmark Nature publication demonstrates...
LogoPressRelease.jpg
Fluidigm Establishes Center of Excellence at NCI-Designated Comprehensive Cancer Center to Advance Imaging Mass Cytometry
10 févr. 2020 16h02 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Landmark Nature Publication Demonstrates the Power of the Fluidigm Hyperion Imaging System to Identify Novel Cellular Signatures That Correlate with Distinct Clinical Outcomes
20 janv. 2020 11h32 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced that a new landmark...
LogoPressRelease.jpg
Fluidigm Provides Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019
14 janv. 2020 08h30 HE | Fluidigm Corporation
Fourth quarter preliminary revenue of $32.0-32.4 million Fiscal year preliminary revenue of $116.7-117.2 million Mass cytometry revenue increased approximately 23 percent for the full fiscal year ...
LogoPressRelease.jpg
Fluidigm Expands Maxpar Antibody Portfolio for High-Multiplex Tissue Imaging
10 déc. 2019 08h30 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced the availability of...
LogoPressRelease.jpg
Fluidigm to Participate in the 31st Annual Piper Jaffray Healthcare Conference
13 nov. 2019 16h05 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...